The team plans to test RI-AG03 in rodents before launching clinical trials. However, prior promising tau-based therapies have failed in clinical trials.

Research on RI-AG03 was funded by charity the Alzheimer's Society UK. Its associate director of research and innovation Dr Richard Oakley welcomed the results.

Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing promise in early trials and lab tests. How the new drug works in the ...

Testing RI-AG03. To test its effectiveness in cells within a living organism, researchers at the University of Southampton then gave the drug to fruit flies that had pathogenic Tau.

They found that RI-AG03 penetrated the cells and reduced the aggregation of tau proteins, too. "What is new here, is that the authors have invented a molecule that binds to both tau hotspot regions.

The increasing knowledge on how protein tau is organized in live cells has shown that the protein forms nanometer-sized hotspots which are different from tau microtubules. These hotspots, essential ...

A team of international researchers has found a promising new drug candidate for the treatment of Alzheimer’s disease. The scientists say they have developed a peptide inhibitor called RI-AG03 ...

Scientists have developed a new drug that targets two key regions of the tau protein, a major contributor to Alzheimer’s disease. The drug, a peptide inhibitor called RI-AG03, successfully ...

Study found that the medication, called RI-AG03, was effective at preventing the buildup of Tau proteins. Nina Massey. Thursday 03 October 2024 15:59 BST. open image in gallery.

Testing RI-AG03. To test its effectiveness in cells within a living organism, researchers at the University of Southampton then gave the drug to fruit flies that had pathogenic Tau.

RI-AG03 targets main promoters of tau protein aggregation at once Oct. 4, 2024 These hotspots, essential for aggregation, include (306)VQIVYK(311) and (275)VQIINK(280) aggregation-promoting hotspots, ...